Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.
about
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsExposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.PharmGKB summary: very important pharmacogene information for SLC22A1Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideHepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.PharmGKB summary: sorafenib pathways.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Polymorphic OCT1: a valid biomarker, but for which drugs?Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.Transporter expression in non-cancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics.Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
P2860
Q27026858-E3A7ADC8-7A45-4315-88C0-6290BCA6E6E9Q28239708-B09E1170-EB52-4656-91C0-4242C640622EQ33411001-9CC76673-E0F7-4352-B3FA-F40DEC6969B1Q33434697-8934AD4B-A594-485B-9DF8-A50A9B3008C4Q33671763-7FB84036-FE60-4220-9CA0-3D3664EB322AQ33891564-04811D3D-7782-4DFF-B9FA-643AD042435BQ35812091-C593C9F0-6218-4E16-9B90-DAF303EF3FF6Q36462972-9ADF6836-D551-4995-8983-D21E23FFA656Q37362692-785DC774-828E-4B78-A5FF-117E2AD6AA6EQ38391227-331E5809-29F7-477A-8C40-B933C11B70F7Q38859468-D5C9FC29-7BE8-4F30-AF32-0D7DFC79B21CQ38864682-41CE2FD2-D2D5-481C-BB7C-B6837F48CCAFQ38888345-D5B07916-7A60-40E5-ACF4-A4ECB72E7D95Q38962943-A2BDE28B-EA34-4AC4-A8DE-83379D4EAB42Q39746291-F3BBF6E7-6517-4119-B582-8D1092BD089DQ40670954-6D27E1E3-CF72-42CD-99EE-05A6DCCFE6E0Q46102176-8FDCA74D-947D-47F9-B3E1-58389DA03BF5Q47130749-9C2A2582-4004-4F34-921F-60BD2F5259D9Q47402203-2A2C798F-AAA9-4CEA-8A68-905929A7A718Q54113908-4D53ABD4-0291-4FC2-A48F-3C76C17E9CD7
P2860
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Sorafenib hepatobiliary dispos ...... tion of generated metabolites.
@en
type
label
Sorafenib hepatobiliary dispos ...... tion of generated metabolites.
@en
prefLabel
Sorafenib hepatobiliary dispos ...... tion of generated metabolites.
@en
P2093
P2860
P356
P1476
Sorafenib hepatobiliary dispos ...... tion of generated metabolites.
@en
P2093
Brandon Swift
Dhiren R Thakker
Dieter Lang
Jin Kyung Lee
Kim L R Brouwer
Mark J Gnoth
Martin Radtke
Noelia Nebot
Tianxiang Han
William R Proctor
P2860
P304
P356
10.1124/DMD.112.048181
P577
2013-03-12T00:00:00Z